CTCs in Cervix Cancer

Inclusion Criteria: * Able to safely provide 15 ml of blood * Able to provide informed consent * Pathologically confirmed invasive cervical cancer * Proof of serotype HPV 16 or HPV 18 positive within 3 years of the study * Patients with stages IIA2 to IVB OR recurrent cervical cancer * For patients with newly diagnosed cervical cancer, they must be enrolled (blood drawn) prior to initiating anti-cancer therapy * For patients with recurrent cervical cancer, they must be enrolled (blood drawn) prior to initiating a new anti-cancer therapy for progression of disease (based on RECIST 1.1 criteria). Patients who have progressed and are moving to best supportive care are eligible. * If patients meet criteria 5.1A 5 above, the following criteria must be met: * At least 21 days have elapsed following treatment with cytotoxic chemotherapy * At least 14 days have elapsed following treatment with biologic therapy * At least 14 days have elapsed following radiation therapy Exclusion Criteria: * History of any cancer other than cervix cancer within the past five years. * History of any known germ-line pathogenic mutation (ie BRCA 1 / 2 or Lynch syndrome, but genetic testing is not required) * Current use of systemic corticosteroids at doses exceeding 10 mg per day of prednisone or its equivalent. * Active infection including hepatitis B, hepatitis C, HIV. * Any patient unable to comply with the study criteria. * Patients taking any anti-inflammatory agents (aspirin, NSAIDs, steroids), within 24 hrs prior to blood draw.